The startup develops radiopharmaceuticals that utilize proprietary imaging and therapeutic molecules to enhance the diagnosis and treatment of metastatic cancer. By targeting both solid and hematologic malignancies, the company provides healthcare professionals with differentiated treatment options that aim to extend patient survival while maintaining favorable safety profiles.
Funding
$261.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic cancers, both solid and hematologic, pose significant challenges in diagnosis and treatment, often requiring differentiated therapeutic options to improve patient survival rates while minimizing adverse effects. Current cancer therapies may lack the precision needed to selectively target tumor cells, leading to off-target toxicity and reduced efficacy.
Solution
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company focused on developing targeted therapies and imaging agents for metastatic cancers. The company leverages a distinctive portfolio of molecules designed to deliver radioisotopes directly to cancer cells with unparalleled precision. By optimizing each component of the molecule—binder, linker, chelator, and radioisotope—Alpha-9 creates bespoke radiopharmaceuticals with high tumor-specific uptake and stability. These radiopharmaceuticals utilize alpha- and beta-emitting isotopes to induce DNA damage in cancer cells, offering the potential for improved efficacy and safety profiles. Alpha-9's approach allows for rapid and cost-effective movement from preclinical studies to clinical trials, with early human studies validating target engagement and payload delivery.
Target Audience
The primary target audience includes healthcare professionals, such as oncologists and nuclear medicine physicians, who require advanced diagnostic and therapeutic tools for managing metastatic cancers.
Features
- Proprietary technology for designing bespoke radiopharmaceuticals optimized for tumor-specific uptake
- Capability to utilize both alpha- and beta-emitting isotopes (e.g., Actinium-225 and Lutetium-177) for therapeutic applications
- Systematic approach to molecule design, optimizing the binder, linker, chelator, and radioisotope components
- In-house formulation expertise targeting week-long shelf-life for final products
- Clinical programs across a range of targets and tumor indications
- Custom-built research facilities equipped for biology, chemistry, in vitro and in vivo radiochemistry work, formulation, and licensed for a diverse array of radioisotopes